Bristol-Myers Squibb Co (XSWX:BMY) Total Tax Payable: CHF716 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:BMY Bristol-Myers Squibb Co XSWX:BMY
78 GF Score
Price CHF50.31
GF Value CHF45.07
! 7 Warning Signs
View Full Analysis

What is Bristol-Myers Squibb Co Total Tax Payable?

Bristol-Myers Squibb Co XSWX:BMY +1.42% 78 Total Tax Payable is CHF716 Mil as of Mar. 2026. GuruFocus rates XSWX:BMY with a GF Score™ of 78/100 and a GF Value™ of CHF45.07. The stock has 7 warning signs investors should review.

Bristol-Myers Squibb Co's Total Tax Payable for the quarter that ended in Mar. 2026 was CHF716 Mil.

Bristol-Myers Squibb Co's quarterly Total Tax Payable declined from Sep. 2025 (CHF814 Mil) to Dec. 2025 (CHF780 Mil) and declined from Dec. 2025 (CHF780 Mil) to Mar. 2026 (CHF716 Mil).

Bristol-Myers Squibb Co's annual Total Tax Payable increased from Dec. 2023 (CHF1,186 Mil) to Dec. 2024 (CHF1,350 Mil) but then declined from Dec. 2024 (CHF1,350 Mil) to Dec. 2025 (CHF780 Mil).

Bristol-Myers Squibb Co Total Tax Payable Related Terms

Bristol-Myers Squibb Co Total Tax Payable Historical Data

* Premium members only.

The historical data trend for Bristol-Myers Squibb Co's Total Tax Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bristol-Myers Squibb Co Total Tax Payable Chart

Bristol-Myers Squibb Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Tax Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 694.43 877.57 1,185.64 1,349.88 780.17

Bristol-Myers Squibb Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Tax Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,284.75 746.52 813.61 780.17 715.66
XSWX:BMY
78GF Score
Bristol-Myers Squibb Co XSWX:BMY
Total Tax Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bristol-Myers Squibb Co Total Tax Payable Calculation

Total Tax Payable is the taxes liability owed to federal, state, and local tax authorities. It is the carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes.

Frequently Asked Questions Learn more about Total Tax Payable →
What does a Total Tax Payable of CHF716 Mil mean?
Bristol-Myers Squibb Co (XSWX:BMY) has a Total Tax Payable of CHF716 Mil as of Mar. 2026. Tax Payable is the taxes liability owed to federal, state, and local tax authorities. View historical data on Bristol-Myers Squibb Co and its competitors.
Is Bristol-Myers Squibb Co's Total Tax Payable too high?
Bristol-Myers Squibb Co's current Total Tax Payable is CHF716 Mil. Overall, Bristol-Myers Squibb Co has a GF Score™ of 78/100, reflecting its overall financial health beyond just this single metric.
How does Bristol-Myers Squibb Co's Total Tax Payable compare to PFE and GILD?
Bristol-Myers Squibb Co's Total Tax Payable of CHF716 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Tax Payable for a Drug Manufacturers company?
A good Total Tax Payable depends on the Drug Manufacturers industry context. However, Total Tax Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Tax Payable mean?
A high Total Tax Payable can signal that a stock is expensive relative to its fundamentals. Tax Payable is the taxes liability owed to federal, state, and local tax authorities. View historical data on Bristol-Myers Squibb Co and its competitors. Bristol-Myers Squibb Co's current Total Tax Payable is CHF716 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bristol-Myers Squibb Co stock overvalued right now?
Bristol-Myers Squibb Co (XSWX:BMY) has a current Total Tax Payable of CHF716 Mil. The stock's GF Value™ is CHF45.07, compared to a current price of CHF50.31 — trading 11.6% above its estimated fair value. The current Total Tax Payable is CHF716 Mil. Bristol-Myers Squibb Co's overall GF Score™ is 78/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Tax Payable calculated?
Total Tax Payable is calculated from a company's financial statements. For Bristol-Myers Squibb Co (XSWX:BMY), the current Total Tax Payable is CHF716 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bristol-Myers Squibb Co (XSWX:BMY) Overvalued in 2026?

Based on GuruFocus' analysis, Bristol-Myers Squibb Co stock appears to be overvalued. The current stock price of CHF50.31 is trading 11.6% above its estimated GF Value™ of CHF45.07.

Key valuation signals for XSWX:BMY:

  • Total Tax Payable: CHF716 Mil
  • GF Value™: CHF45.07 vs. price of CHF50.31 (11.6% above fair value)
  • GF Score™: 78/100 with 7 warning signs

No single metric tells the full story. See the XSWX:BMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bristol-Myers Squibb Co Business Description

Address Route 206 and Province Line Road, Princeton, New Jersey, NJ, USA, 08543
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
78GF Score

Get the complete analysis for XSWX:BMY

Total Tax Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF50.31
Price
CHF45.07
GF Value